Genetic and atherosclerotic plaque immunohistochemical analyses do not associate reduced sclerostin expression with cardiovascular events
Authors:
Preprint
Abstract
The sclerostin antibody romosozumab increases bone formation and decreases bone resorption, leading to increased bone mass, bone mineral density and bone strength, and reduced fracture risk. In a clinical study versus alendronate in postmenopausal women (ARCH), an imbalance in adjudicated serious cardiovascular (CV) events driven by an increase in myocardial infarction (MI) and stroke was observed. To investigate whether inhibition of sclerostin in atherosclerotic plaques may have contributed to this imbalance, sclerostin was immunostained in human plaques to determine whether it was detected in regions relevant to plaque stability. Additionally, genetic variants associated with lifelong reduced sclerostin expression were explored for associations with phenotypes including those related to bone physiology and CV risk factors/events in a population-based phenome-wide association study (PheWAS). Sclerostin expression was absent (67%) or reduced in atherosclerotic plaques and when present was in deeper regions of the plaque/wall and not in areas considered relevant to plaque stability (fibrous cap and endothelium). Natural genetic modulation of sclerostin by variants with a significant positive effect on bone physiology showed no association with lifetime risk of MI or stroke. These data do not support a causal association between sclerostin inhibition and increased risk of serious cardiovascular events.Keywords
All Related Versions
- Published version: Journal of Bone and Mineral Research, 36 (7), 1326.
This publication has 80 references indexed in Scilit:
- Novel actions of sclerostin on boneJournal of Molecular Endocrinology, 2019
- Romosozumab for the treatment of osteoporosisOsteoporosis and Sarcopenia, 2018
- Wnt Signaling Pathway Inhibitor Sclerostin Inhibits Angiotensin II–Induced Aortic Aneurysm and AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2017
- Carcinogenicity risk assessment of romosozumab: A review of scientific weight-of-evidence and findings in a rat lifetime pharmacology studyRegulatory Toxicology and Pharmacology, 2016
- Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional studyBMC Nephrology, 2013
- Novel insights into osteogenesis and matrix remodelling associated with calcific uraemic arteriolopathyNephrology Dialysis Transplantation, 2012
- Proteomics Characterization of Extracellular Space Components in the Human AortaMolecular & Cellular Proteomics, 2010
- Sclerostin is a delayed secreted product of osteocytes that inhibits bone formationThe FASEB Journal, 2005
- Bone Dysplasia Sclerosteosis Results from Loss of the SOST Gene Product, a Novel Cystine Knot–Containing ProteinThe American Journal of Human Genetics, 2001
- Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)Human Molecular Genetics, 2001